Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871282 · ClinicalTrials.gov registry record · Phase 2
A Study of AL102 in Patients With Progressing Desmoid Tumors
A Phase 2 study of Desmoid Tumor and Desmoid, sponsored by Immunome.
- Active
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
- 20
- Study locations
NCT04871282: Active Phase 2 study of Desmoid Tumor and Desmoid, sponsored by Immunome.
NCT04871282 is a Phase 2 study of Desmoid Tumor and Desmoid that is active but no longer recruiting, run by Immunome. The registered enrollment target is 198 participants, above the 40-participant average among 4 other Desmoid Tumor trials with a reported enrollment target (395% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04871282, a Phase 2 study of Desmoid Tumor and Desmoid, is active but no longer recruiting, sponsored by Immunome.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Primary Outcome
Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by as defined by the frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AL102
Study Locations (20)
California
- City of Hope - Duarte
- Sarcoma Oncology Research Center - Santa Monica
- University of California at Los Angeles Hematology/Oncology - Santa Monica
- Stanford University Medical Center - Stanford
Pennsylvania
- Jefferson University Hospital - Philadelphia
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center - Pittsburgh
Missouri
- Jefferson City Medical Group - Jefferson City
- Washington University - St Louis
New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University Wexner Medical Center - Columbus
Arizona
- Mayo Clinic - Pheonix
Florida
- Mayo Clinic - Jacksonville
Illinois
- NorthShore University Health System - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT04871282 still lists
NCT04871282 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, above the 40-participant average among 4 other Desmoid Tumor trials with a reported enrollment target (395% higher).
The record links to 2 conditions, with Desmoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04871282 names 20 study sites across 12 states, led by California, Pennsylvania, Missouri.
Frequently Asked Questions
What is clinical trial NCT04871282 about?
NCT04871282 is a clinical study titled "A Study of AL102 in Patients With Progressing Desmoid Tumors". The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
What is the current status of trial NCT04871282?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2021-03-30. Estimated completion is 2026-10.
What conditions does trial NCT04871282 study?
This clinical trial studies the following conditions: Desmoid Tumor, Desmoid.
What interventions are being tested in trial NCT04871282?
The interventions under investigation include: Placebo (OTHER), AL102 (DRUG).
Who is sponsoring clinical trial NCT04871282?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04871282 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Desmoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Cryoablation and Nirogacestat for Desmoid Tumor
RECRUITING · Phase 2
-
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
COMPLETED · Phase 2
-
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
COMPLETED · Phase 2
-
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI